about
The magnitude of hedgehog signaling activity defines skin tumor phenotypeCombined Treatments with Photodynamic Therapy for Non-Melanoma Skin CancerCutaneous squamous cell cancer (cSCC) risk and the human leukocyte antigen (HLA) system.E-cadherin suppression directs cytoskeletal rearrangement and intraepithelial tumor cell migration in 3D human skin equivalents.PAI-1 Regulates the Invasive Phenotype in Human Cutaneous Squamous Cell Carcinoma.The secreted form of a melanocyte membrane-bound glycoprotein (Pmel17/gp100) is released by ectodomain shedding.Glycoprotein nonmetastatic melanoma protein b, a melanocytic cell marker, is a melanosome-specific and proteolytically released protein.The skin cancer chemotherapeutic agent ingenol-3-angelate (PEP005) is a substrate for the epidermal multidrug transporter (ABCB1) and targets tumor vasculature.Polyamines and nonmelanoma skin cancer.G Protein betagamma subunits augment UVB-induced apoptosis by stimulating the release of soluble heparin-binding epidermal growth factor from human keratinocytes.IL-1R-MyD88 signaling in keratinocyte transformation and carcinogenesisSubamolide B Isolated from Medicinal Plant Cinnamomum subavenium Induces Cytotoxicity in Human Cutaneous Squamous Cell Carcinoma Cells through Mitochondrial and CHOP-Dependent Cell Death PathwaysOrnithine decarboxylase is a target for chemoprevention of basal and squamous cell carcinomas in Ptch1+/- mice.PTCH mutations in basal cell carcinomas from azathioprine-treated organ transplant recipients.DNA damage, apoptosis and langerhans cells--Activators of UV-induced immune tolerance.Risk of skin cancer in patients with diabetes mellitus: A nationwide retrospective cohort study in Taiwan.Epithelial stem cell mutations that promote squamous cell carcinoma metastasis.Oxidative stress and skin cancer: an overview.Suppression of E-cadherin function drives the early stages of Ras-induced squamous cell carcinoma through upregulation of FAK and Src.Keratinocyte-specific Smad2 ablation results in increased epithelial-mesenchymal transition during skin cancer formation and progression.RalA suppresses early stages of Ras-induced squamous cell carcinoma progression.An inducible mouse model for skin cancer reveals distinct roles for gain- and loss-of-function p53 mutations.PAI-1 is a Critical Upstream Regulator of the TGF-beta1/EGF-Induced Invasive Phenotype in Mutant p53 Human Cutaneous Squamous Cell Carcinoma.Basal cell carcinomas in mice arise from hair follicle stem cells and multiple epithelial progenitor populations.Expression of endothelins and their receptors in nonmelanoma skin cancers.TGF-beta1-Induced Expression of the Poor Prognosis SERPINE1/PAI-1 Gene Requires EGFR Signaling: A New Target for Anti-EGFR Therapy.Keratinocyte p38δ loss inhibits Ras-induced tumor formation, while systemic p38δ loss enhances skin inflammation in the early phase of chemical carcinogenesis in mouse skin.[Carcinogenesis: defect control systems and options for molecular therapy].Skin-cancer stem cells outwitted
P2860
Q24671053-C82BE2F0-6FF6-4F54-BF1B-196BEBFC8476Q26777814-32C75CA2-6716-424E-9D08-B56FC1C477F5Q30235983-9FB02FBB-BC6A-41B8-845A-0AD267FA7A9AQ30493336-FD06E173-53E1-4125-A6BB-E54EE2ED6FD6Q33693105-F8EE9932-4090-49CB-9CF0-8763579B2E12Q33694588-3DB6F864-BC46-4564-B7D6-23612977B146Q33891014-BD0D1CBF-93ED-403E-8CDA-9DB04A5EF3CAQ33891947-52BAFD21-01BA-4EDB-B35D-24017B1B9B86Q34603550-F9750C2F-AC75-4908-B05F-340524B1F3CAQ34634264-FB70437F-AB6B-431F-B9DC-604C27077469Q36193541-1BDDD8CC-2890-4279-9FFB-83E45EB37E77Q36723160-9C3BB48B-15DA-4B92-AD95-91FE0179556BQ36752431-6C7AD287-6A2F-49ED-B7AC-A90D8E109806Q36944052-47F6516D-773A-47B4-AF59-978F8C77C90AQ37076474-1868AD77-9D44-4C4B-9699-81C681E7B9AAQ37078107-5A96EEB7-E9A0-42BE-BDFB-F2BC1E6DF580Q37200826-5110E66D-9DA4-46E9-9CCE-5F05F2DE852BQ38178606-96F3B1FC-6899-4DF8-815F-F298F74FE96EQ38427449-E87CD649-B814-4CB5-82B6-52D98E78BAD2Q39790068-D1BDE7CF-CEA0-435D-BD8C-2E3FB0E55241Q39791607-FC2AB2C3-1934-4FE3-BF25-5E7BA9AD1327Q40198133-82AA7EF8-5F76-4E76-A9DC-607599C6CA59Q41857137-1C69DBDD-9A65-462B-B663-08136F346683Q42487221-C88C56A1-B143-4EDC-BF16-6C1B45A13D6FQ42507181-E74BBE52-2199-4E04-8CA9-9786027E7C8BQ43146931-FB6650A7-B84E-4829-8842-5E04FBEAAFE5Q52960714-4CFCCAE4-F700-4248-94F4-499574AD1625Q53352349-936D4FB0-4269-4748-B060-7620085002A4Q57188916-9FEE206D-F8A9-4C36-8F1E-F90AB0B278A8
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Progress in cutaneous cancer research.
@ast
Progress in cutaneous cancer research.
@en
type
label
Progress in cutaneous cancer research.
@ast
Progress in cutaneous cancer research.
@en
prefLabel
Progress in cutaneous cancer research.
@ast
Progress in cutaneous cancer research.
@en
P2093
P1476
Progress in cutaneous cancer research.
@en
P2093
Andrzej Dlugosz
Glenn Merlino
Stuart H Yuspa
P356
10.1046/J.1523-1747.2002.19631.X
P577
2002-12-01T00:00:00Z
P5875
P6179
1023761636